For how we live.
A phase 2 trial gave ivonescimab, alone or with chemotherapy, to people with operable non-small-cell lung cancer. With chemotherapy, 70% had a major pathological response — but there was no control arm.
In PANKU-Lung01, 432 people with EGFR-mutated NSCLC that progressed on a third-generation EGFR tablet got izalontamab brengitecan or chemotherapy. Median progression-free survival was 11.1 versus 5.7 months.
In HERON-Lung01, 498 people in China with EGFR-mutated NSCLC that had progressed after a targeted drug were randomised to ruzaltatug rezetecan or chemotherapy. Median progression-free survival was 8.3 versus 5.4 months.
Five-year follow-up of a Chinese randomised trial shows paclitaxel–cisplatin–capecitabine before chemoradiotherapy lifted failure-free survival from 63% to 78% in high-risk disease — at the cost of more toxicity.
In KEYNOTE-B15/EV-304, perioperative enfortumab vedotin plus pembrolizumab lifted two-year event-free survival to 79.4% from 66.2% against standard cisplatin-based chemotherapy in patients fit for it.
A three-year update of RATIONALE-309 found tislelizumab plus chemotherapy lengthened median progression-free survival to 9.6 months from 7.4. The overall-survival gain was not statistically significant on its own.